The use of DMX-200 in combination with an ARB is based on increased inhibition of CCR2 signaling in cell-based pharmacology studies, and in vivo studies in the subtotal nephrectomy rat model of FSGS, where the combination of DMX-200 and an ARB provided a greater reduction in proteinuria, macrophage infiltration, and podocyte loss than vehicle or either antagonist alone.7 The gene discussed is CCR2; the disease is focal segmental glomerulosclerosis.